21 October 2011
EMA/851133/2011
Press Office

Start of community reviews

Adopted at the CHMP meeting of 17-20 October 2011

Table 1. Start of safety reviews for centrally authorised medicines

Name	INN	Type of procedure	Scope
Protelos/Osseor	strontium ranelate	Article 20 Referral of Regulation (EC) 726/2004	Procedure triggered by the European Commission asking for an EU-wide review of the benefit-risk balance for Protelos/Osseor. This follows new recommendations issued by the French medicines Agency (Afssaps) on 7 October 2011 to healthcare professionals in France restricting the use of the medicine.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8669
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Table 2. Start of safety reviews for non-centrally authorised medicines

Name	INN	Type of procedure	Scope
Non-selective NSAIDs (non-steroidal anti-inflammatory drugs)		Article 5(3) of Regulation (EC) 726/2004	Procedure triggered by United Kingdom asking for a scientific opinion on the cardiovascular safety of NSAIDs in view of new epidemiological studies which became recently available.